Compare WKSP & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKSP | COCP |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 14.1M |
| IPO Year | N/A | N/A |
| Metric | WKSP | COCP |
|---|---|---|
| Price | $2.56 | $1.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $12.83 | $6.00 |
| AVG Volume (30 Days) | ★ 199.3K | 56.4K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,286,679.00 | N/A |
| Revenue This Year | $142.95 | N/A |
| Revenue Next Year | $109.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 123.37 | N/A |
| 52 Week Low | $1.92 | $0.90 |
| 52 Week High | $12.00 | $3.26 |
| Indicator | WKSP | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 46.33 | 50.36 |
| Support Level | $2.62 | $1.01 |
| Resistance Level | $2.97 | $1.10 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 48.70 | 74.89 |
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).